Publications

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.

Jensen IS, Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin lymphoma in the United States: A budgetary impact analysis. Abstract C14. Academy of Managed Care Pharmacy 26^th Annual Meeting & Expo 2014.

Jensen IS, Halbert RJ, Grosvenor A, Swartz E, Rossi G, Naoshy S, et al. Incorporating stakeholder input into budget impact models to compare stem cell mobilization strategies. Abstract PCN43. ISPOR 18th Annual International Meeting, 2013.

Chia VM, O’Malley CD, Danese MD, Lindquist KJ, Gleeson ML, Kelsh MA, et al. 2013. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol 129(2):346–352. doi: 10.1016/j.ygyno.2013.02.014.

Lowe KA, Chia VM, Taylor A, O’Malley C, Kelsh M, Mohamed M, et al. 2013. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 130(1): 107–114.

Olchanski N, McInnis-Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH. 2013. The economic burden of treatment-resistant depression. Clin Ther 35(4):512-522; doi: 10.1016/j.clinthera.2012.09.001.

Sacks NC. 2013. Avoidable costs in U.S. healthcare: The $200 billion opportunity from using medicines more responsibly. IMS Health, June.

Sacks NC, Burgess JF, Cabral HJ, Pizer SD, McDonnell, ME. 2013. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med 28(7):876–885.

Cyr P, Sidhu M, Hussain R, Hromin T, Jensen I, Kuan R. Dual-acting osmotic and stimulant laxative for bowel cleansing in an elderly population: A US payer budget impact analysis. Abstract PCN22. ISPOR 18th Annual International Meeting, 2013.

Proctor DM, Suh M, Thompson CM, Harris MA. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.